Dr. Baracchini joined Xencor as its Chief Business Officer in January 2010. Dr. Baracchini has over 20 years experience in structuring and negotiating research and development partnerships, mergers and acquisitions, and in-licensing agreements. To date, he has negotiated more than 80 business transactions with multinational and Asian pharmaceutical firms, biotechnology companies, and prominent universities, leading to transactions valued in excess of $5.3 billion. Additionally, Dr. Baracchini has been a key member of executive teams that have risen over $600 million in private and public financing, and have successfully completed two IPOs.
Most recently, Dr. Baracchini served as Senior Vice President of Business Development at Metabasis Therapeutics form 2002 and until its merger with Ligand Pharmaceuticals in 2009. Prior to joining Metabasis, Dr. Baracchini held the position of Vice President of Business Development at Elitra Pharmaceuticals from 1999 to 2002. He served as the Director of Business Development at Agouron Pharmaceuticals from 1996 through it’s acquisition by Warner-Lambert in 1999. Dr. Baracchini was the Assistant Director of Business Development at Isis Pharmaceuticals from 1992 to 1996. From 1988 to 1992 Dr. Baracchini performed postdoctoral research at UCSD and The Scripps Research Institute. Dr. Baracchini holds a Ph.D. in molecular and cell biology from the University of Texas at Dallas, an M.B.A. from the University of California, Irvine, and a B.S. in microbiology from the University of Notre Dame.